AnGes, Inc. (TYO:4563)

Japan · Delayed Price · Currency is JPY

46.00

-1.00 (-2.13%)

Jun 24, 2026, 2:03 PM JST

-28.13% (1Y)

Market Cap	18.75B -19.7%
Revenue (ttm)	908.00M +29.9%
Net Income	-4.96B
EPS	-13.21
Shares Out	398.83M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,078,900
Open	47.00
Previous Close	47.00
Day's Range	46.00 - 49.00
52-Week Range	44.00 - 120.00
Beta	0.64
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About AnGes

AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The company was incorporated in 1999 and is headquartered in Ibaraki, Japan. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1999

Employees 56

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4563

Full Company Profile

Financial Performance

In 2025, AnGes's revenue was 874.00 million, an increase of 35.93% compared to the previous year's 643.00 million. Losses were -5.12 billion, -81.79% less than in 2024.

Financial Statements